Helix BioPharmaHBPCF 28 3-Year RORE % is -37.69 as of Apr. 2026. GuruFocus rates HBPCF with a GF Score™ of 28/100. Among 1,295 Biotechnology companies, Helix BioPharma ranks worse than 73.98% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Helix BioPharma's 3-Year RORE % for the quarter that ended in Apr. 2026 was -37.69%.
The industry rank for Helix BioPharma's 3-Year RORE % or its related term are showing as below:
HBPCF's 3-Year RORE % is ranked worse than 73.98% of 1295
companies
in the Biotechnology industry
Industry Median: -11.53
vs HBPCF: -37.69
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Helix BioPharma 3-Year RORE % Related Terms
Helix BioPharma 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Helix BioPharma's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBPCF vs VRTX, REGN, ALNY: 3-Year RORE % Comparison
For the Biotechnology subindustry, Helix BioPharma's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helix BioPharma 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Helix BioPharma's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Helix BioPharma's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Apr. 2026 and 3-year before.
Helix BioPharma (HBPCF) has a 3-Year RORE % of -37.69 as of Apr. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Helix BioPharma and its competitors. According to the industry distribution chart, Helix BioPharma ranks #958 out of 1295 companies in the Biotechnology industry, placing it in the top 74%.
Is Helix BioPharma's 3-Year RORE % too high?
Helix BioPharma's current 3-Year RORE % is -37.69. Based on the distribution chart, Helix BioPharma ranks #958 out of 1295 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helix BioPharma ranks #958 out of 1295 companies for 3-Year RORE %. This places Helix BioPharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Helix BioPharma and its competitors. Helix BioPharma's current 3-Year RORE % is -37.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current 3-Year RORE % of -37.69. The current 3-Year RORE % is -37.69. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current 3-Year RORE % is -37.69 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score
Get the complete analysis for HBPCF
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HBPCF has been successfully added to your 
